Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Extranodal Lymphoma, Intravascular Large B-Cell Lymphoma, Lymphoma, Marginal Zone Lymphoma, Mucosa-Associated Lymphoid Tissue Lymphoma, NK/T-Cell Lymphoma, Nasal and Nasal-Type
Conditions
Keywords
LYMPHOMA, EXTRANODAL
Brief summary
The aim of this study is to retrospectively collect clinical information on patients with extranodal or rare lymphomas, and to explore the best treatment strategy for these lymphomas in the real-world population.
Detailed description
Lymphoma is a highly common malignant tumor in Asia. For specific extra-abdominal sites or rare pathological subtypes of lymphoma, traditional chemotherapy protocols often cannot provide satisfactory results for patients. This study aims to retrospectively collect clinical information on patients with extranodal lymphoma or rare pathological subtype lymphoma, including the distribution of involved sites, clinical and molecular characteristics of different lymphoma subtypes, clinical treatment protocols, and prognosis, to explore the best treatment strategy for these lymphomas in the real-world population.
Interventions
No interventions need to be specified for this study
Sponsors
Nanfang Hospital, Southern Medical University
Fujian Medical University Union Hospital
Peking University Third Hospital
Peking University People's Hospital
Peking Union Medical College Hospital
Beijing Hospital
The Second Affiliated Hospital of Dalian Medical University
The First Affiliated Hospital of Guangzhou Medical University
Henan Provincial People's Hospital
Hunan Cancer Hospital
Henan Cancer Hospital
The First Hospital of Jilin University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Affiliated Hospital of Nantong University
The First Affiliated Hospital of Xiamen University
Shandong Provincial Hospital
Shanxi Province Cancer Hospital
RenJi Hospital
Beijing Friendship Hospital
West China Hospital
The First Affiliated Hospital of Soochow University
Tongji Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sun Yat-sen University
Chongqing University Cancer Hospital
Anhui Provincial Cancer Hospital
The General Hospital of Northern Theater Command
Qilu Hospital of Shandong University
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
The Affiliated Hospital Of Guizhou Medical University
Wuhan TongJi Hospital
General Hospital of Ningxia Medical University
The First Affiliated Hospital of Nanchang University
The First Affiliated Hospital with Nanjing Medical University
Anshan Central Hospital
Hainan Cancer Hospital
Fifth Affiliated Hospital of Guangzhou Medical University
The First Affiliated Hospital of Anhui Medical University
The Affiliated Hospital of Xuzhou Medical University
First Affiliated Hospital of Harbin Medical University
Zhujiang Hospital
Ruijin Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years (including 18 years old). 2. Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined; Or patients newly diagnosed with non-Hodgkin lymphoma of rare pathological types, including IVLBCL, SMZL, ALCL, AITL, MALTL. 3. Patients who have received systematic clinical treatment. 4. Patients with measurable lesions, at least containing one effective evaluation of efficacy.
Exclusion criteria
1. Patients who only receive supportive treatment. 2. Patients who cannot obtain effective evaluation data of efficacy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | Baseline up to data cut-off (up to approximately 1 year) | Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause. |
| Overall Survival (OS) | Baseline up to data cut-off (up to approximately 1 year) | Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical characteristics form | Baseline up to data cut-off (up to approximately 1 year) | Clinical characteristics from data filled into registry forms by physicians and data managers, including but not limited to values of lactate dehydrogenase, clinical stage, performance status, age ≥ 60 years and number and location of extranodal localizations. |
| Biological characteristics form | Baseline up to data cut-off (up to approximately 1 year) | Biological characteristics from data filled into registry forms by physicians and data managers, such as immunohistochemical differences and genetic mutation characteristics of non-hodgkin´s lymphomas. |
Countries
China
Contacts
Primary ContactWeili Prof. Zhao
Backup ContactPengpeng Prof. Xu
Outcome results
None listed